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Abstract
Purpose The aim of this study is to validate medication prox-
ies for the identification of children diagnosed with atopic
disorders that can be applied in various types of epidemiolog-
ical research.
Methods Records of 7439 children, aged between 0 and
10 years, in the period 2001 until 2010, were retrieved from
the Registration Network Groningen database, a general prac-
titioners database in the north-eastern part of the Netherlands.
The sensitivity and positive predictive value (PPV) of 22med-
ication proxies for the identification of children diagnosed
with atopic disorders (asthma, atopic dermatitis, and allergic
rhinitis) were computed using the registered diagnoses as gold
standards. In addition, different capture periods (1 year, half
year, and length of study period) for the detection of prescrip-
tions were tested for all the medication proxies.
Results The highest PPV (0.84, 95 % CI 0.81–0.87) in com-
bination with a sufficient sensitivity value (0.54, 95 % CI
0.50–0.57) for the identification of children diagnosed with
asthma was yielded for the medication proxy, ≥2 prescriptions
for anti-asthma medication within 1 year, including 1 inhaled
steroid. PPVand sensitivity were even higher in the age group
6–10 years. The proxies designed for the identification of
children diagnosed with atopic dermatitis and allergic rhinitis
yielded only high PPVs (≥0.75) in combination with low sen-
sitivity values (≤0.22). Altering the capture period for the de-
tection of prescriptions to half a year or the length of the study
period only affected sensitivity values.
Conclusion Children diagnosed with asthma can be identified
reliably with a range of medication proxies. The use of pre-
scription data for the identification of children diagnosed with
atopic dermatitis and allergic rhinitis is questionable.
Keywords Prescriptions . Specificity . Sensitivity . Atopic
diseases . Asthma . Eczema . Hay fever
Introduction
Pharmacy databases with large numbers of prescriptions
can provide valuable information for observational stud-
ies [1]. However, the validity of using prescription data
for the identification of children with atopic diseases in
epidemiological research has been questioned, especially
in children [2–8].
Various efforts have already been made to validate
methods for the identification of asthma patients with
prescription data [3–8]. A former study of our group
investigated the accuracy of the use of several medica-
tion proxies for the identification of asthma patients
(age 19–49) and showed that asthma patients could be
identified reliably from prescription data [5]. However,
results from an adult patient population cannot directly
be generalized to a population of children, especially
not in the case of asthma [9]. Making an asthma
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diagnosis in children is difficult since objective lung
tests cannot be performed in patients under the age of
6 [9]. In addition, children may use anti-asthma medi-
cation for other indications than adults (acute bronchitis
versus chronic obstructive pulmonary disease) [2].
Recent studies developed a valid method for the identi-
fication of asthmatic children (age 4.5–17 years) using
prescription data [3, 7, 8]. However, for different study
purposes, different accuracy measures (sensitivity, spec-
ificity, positive predictive value, negative predictive val-
ue) are important and hence various proxies are needed
to be developed for the use in various epidemiological
studies [10]. In addition, children with asthma often
have concomitant allergic diseases like atopic dermatitis
or allergic rhinitis, due to common pathogenesis [11].
To our knowledge, only one study has focused on the
validation of an identification tool for children with
atopic dermatitis and concluded that the identification
of children with this disease based on a medication
proxy was insufficient [8]. Since only one medication
proxy was tested and only positive predictive values
were reported, there is still need for the validation of
other proxies for atopic dermatitis. In addition, no stud-
ies have focused on the identification of children diag-
nosed with allergic rhinitis.
Therefore, the main objective of this study was to determine
reliable medication proxies for the identification of children
diagnosed with atopic diseases (asthma, atopic dermatitis, and




This register-based cross-sectional study was performed with
data from the Registration Network Groningen (RNG) data-
base. This network was established in 1989 and consists of
patient registrations of three general practices with 17 general
practitioners (GPs) in the north-eastern part of the Nether-
lands. The RNG includes a dynamic population with an aver-
age annual population of approximately 30,000 patients. Pa-
tients were anonymized and identified with a unique patient
number. This network contains information about patient
characteristics, diagnoses, and prescription records for each
patient. Each prescription contains an anatomical therapeutic
chemical code (ATC-code), and each diagnosis is described
with the International Classification for Primary Care (ICPC)
code [12]. GPs are trained specifically to work with the coding
system, and coding of ICPC and ATC codes was proven to be
accurate in previous studies [7, 13]. In the Netherlands, pa-
tients are registered to a single GP, so records in the RNG
database can be assumed to be complete for the individual
patient [14]. Diagnoses and prescriptions from specialists are
included in the database if these are communicated to one of
the GPs by a so-called retour letter. More information about
the database is described elsewhere [15, 16].
Study population
Patient records from 01 January 2001 until 31 December 2010
were selected from the RNG database. Patients were included
in the study if they had at least one physician encounter (visit,
telephone consultation, or prescription request) during the
study period and were aged between 0 and 10 years at the
moment of encounter.
Prescription data
Data were obtained for all prescriptions regarding drugs
for obstructive airway diseases (ATC R03), dermatologi-
cal preparations with corticosteroids (ATC D07), other
agents for the treatment of dermatitis (ATC D11AH), na-
sal preparations (R01), and systemic antihistamines (ATC
R06) prescribed from 01 January 2001 until 31 December
2010. Twenty-two medication proxies (listed in Table 1)
with a capture period of 1 year were designed for the
identification of children diagnosed with atopic diseases,
according to the Dutch guidelines for general practitioners
[17–19]. The accuracy measures sensitivity and PPV were
calculated for all medication proxies. Specificity and NPV
were not calculated since these values will be artificially
high, due to the large number of non-allergic patients
included in the study population [5].
Analysis
A recorded diagnosis of either atopic dermatitis (ICPC
S87), asthma (ICPC R96), or allergic rhinitis (ICPC
R97) during the study period was defined as the gold
standard. For each medication proxy, the sensitivity, pos-
itive predictive value (PPV), and 95 % confidence inter-
vals (95 % CI) were calculated. In additional analyses,
different capture periods for the detection of prescriptions
(half year and total study period) were tested for all the
medication proxies. Since the PPV is dependent on the
prevalence of the indication in a population, a sensitivity
analysis was performed for the proxy ≥2 inhaled steroids
within a year. In this extra analysis, positive predictive
values were calculated for a reasonable range of preva-
lence numbers of asthma, derived from an ISAAC study
into the worldwide trends in asthma prevalence [20]. All
analyses were conducted using the IBM SPSS Statistics
20 version.
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Results
In total, 7439 children until the age of 10 years were included
in the study. Of these children, 1835 (24.7 %) had a registered
diagnosis of an allergic disorder (asthma, atopic dermatitis, or
allergic rhinitis) in their records. The diagnosis asthma (ICPC
R96) was registered in 809 (10.9 %) children (Table 2), atopic
dermatitis (ICPC S87) in 985 (13.2 %) children (Table 3), and
allergic rhinitis (ICPC R97) in 419 (5.6 %) children (Table 4).
Drugs for obstructive airway disease (ATC R03) were used by
744 (10.0 %) children, dermal corticosteroids (ATC D07) by
1990 (26.8 %) children, and nasal antihistamines (ATC
R01AC) or nasal corticosteroids (R01AD) by 518 (7.0 %)
children.
Validation of the medication proxies for the identification
of children diagnosed with asthma
In Table 5, the sensitivity and PPV of the eight medication
proxies for the identification of children diagnosed with asth-
ma are shown. When a capture period of 1 year was applied,
medication proxy 1, receiving ≥1 prescription for any anti-
asthmatic drug, yielded the highest sensitivity of 0.92 (95 %
CI 0.90–0.94). However, only half of the identified children
with this proxy had a registered diagnosis of asthma (PPV
0.54, 95 % CI 0.51–0.57). Table 2 shows that of the children
that got prescribed anti-asthma drugs, 28.2 % had a diagnosis
of acute bronchitis and/or 24.3% a diagnosis of cough without
a concomitant asthma diagnosis. Of the children who got pre-
scribed inhaled corticosteroids, only 16.8 and 14.3 % had a
diagnosis of acute bronchitis or cough without a concomitant
asthma diagnosis, respectively (Table 2). Proxies that included
inhaled corticosteroids (nr 2, 4, and 6) yielded therefore higher
PPVs (0.76, 0.84, and 0.87, respectively) for the identification
of children with an asthma diagnosis. In addition, including
≥2 prescriptions for anti-asthma drugs increased the PPV as
well (Fig. 1).
Validation of the medication proxies for the identification
of children diagnosed with atopic dermatitis
In Table 5, the sensitivity and PPVof the six medication prox-
ies for the identification of children diagnosed with atopic
dermatitis are shown. When a capture period of 1 year was
Table 1 Medication proxies used for the identification of children diagnosed with the atopic disorders asthma, atopic dermatitis, and allergic rhinitis
Indication (ICPC code) nr Medication proxies
Asthma (ICPC R96) 1 ≥1 prescription for an inhaled anti-asthma drug (ATC R03)
2 ≥1 prescription for an inhaled corticosteroid (ATC R03AK, R03BA)
3 ≥2 prescriptions for an inhaled anti-asthma drug (ATC R03)
4 ≥1 inhaled steroid (ATC R03AK, R03BA) + ≥1 inhaled other anti-asthma drug (ATC R03)
5 ≥3 prescriptions for an inhaled anti-asthma drug (ATC R03)
6 ≥2 prescriptions for an inhaled corticosteroid (ATC R03AK, R03BA)
7 ≥4 prescriptions for an inhaled anti-asthma drug (ATC R03)
8 ≥5 prescriptions for an inhaled anti-asthma drug (ATC R03)
Atopic dermatitis (ICPC S87) 9 ≥1 prescription for a dermal steroid (ATC D07)
10 ≥1 prescription for an ointment with an immunosuppressant (ATC D11)
11 ≥2 prescriptions for a dermal steroid (ATC D07)
12 ≥3 prescriptions for a dermal steroid (ATC D07)
13 ≥4 prescriptions for a dermal steroid (ATC D07)
14 ≥5 prescriptions for a dermal steroid (ATC D07)
Allergic rhinitis (ICPC R97) 15 ≥1 prescription for a systemic antihistamine (ATC R06)
16 ≥1 prescription for a nasal antihistamine (ATC R01AC)
17 ≥1 prescription for a nasal corticosteroid (ATC R01AD)
18 ≥2 prescriptions for systemic antihistamines (ATC R06), nasal antihistamines (ATC R01AC)
or nasal steroids (ATC R01AD)
19 ≥3 prescriptions for systemic antihistamines (ATC R06), nasal antihistamines (ATC R01AC)
or nasal steroids (ATC R01AD)
20 ≥2 prescriptions for a nasal corticosteroid (ATC R01AD)
21 ≥4 prescriptions for systemic antihistamines (ATC R06), nasal antihistamines (ATC R01AC)
or nasal steroids (ATC R01AD)
22 ≥5 prescriptions for systemic antihistamines (ATC R06), nasal antihistamines (ATC R01AC)
or nasal steroids (ATC R01AD)
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applied, medication proxy 9, receiving at least 1 prescription
for dermal corticosteroids, yielded the highest sensitivity of
0.80 (95 % CI 0.77–0.82). However, only 39 % of the iden-
tified children had a registered diagnosis of atopic dermatitis
(PPV 0.39, 95 % CI 0.37–0.41). Table 3 shows that of the
children who got prescribed dermal corticosteroids, 37.6 %
had been diagnosed with the ICPC code for contact
dermatitis/other dermatitis. Medication proxy 13, receiving
at least 4 prescriptions for dermal steroids within a year,
yielded a higher PPVof 0.75 (95 % CI 0.65–0.85). However,
only 12 % of the children diagnosed with atopic dermatitis
were detected.
Validation of the medication proxies for the identification
of children diagnosed with allergic rhinitis
In Table 5, the sensitivity and PPV of the nine medication
proxies for the identification of children diagnosed with aller-
gic rhinitis are shown. When a capture period of 1 year was
applied, medication proxy 15, receiving at least 1 prescription
for a anithistamine, yielded the highest sensitivity of 0.72
(95 % CI 0.68–0.76). However, only 23 % of the identified
children had a diagnosis of allergic rhinitis (PPV 0.23, 95 %
CI 0.20–0.25). Medication proxy 16, receiving at least 1 pre-
scription for nasal antihistamine, yielded a higher PPVof 0.87
(95 % CI 0.81–0.93). However, only 22 % of the children
diagnosed with allergic rhinitis were detected. Table 4
showed that of the children who got prescribed nasal antihis-
tamines, 27.2 % received the diagnosis asthma without a con-
comitant diagnosis of allergic rhinitis.
Variation of the capture period for the detection of pre-
scriptions had more effect on sensitivity values (maximum
change 400 % for proxy 14) than that on the PPVs (max-
imum change of 18 % for proxy 20) for the identification
of children diagnosed with asthma, atopic dermatitis, and
allergic rhinitis.
Additional analyses, in which the population was stratified
by age, showed that accuracy measures of the proxies de-
signed for the identification of children diagnosed with atopic
dermatitis were higher in the age group 0–5 years (Table 6).
On the contrary, accuracy measures of the proxies designed
for the identification of children diagnosed with asthma and
allergic rhinitis were higher in the age group 6–10 years
(Table 6).
Sensitivity analyses
The results of the sensitivity analyses on the PPVs of the
proxies ≥2 inhaled steroids in a year were presented in
Fig. 2. This figure showed that the PPV for the identification
of children diagnosed with asthma was accurate for a reason-
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Discussion
The current study showed that accuracy measures of the med-
ication proxies for asthma were relatively high, especially in
children older than 5 years. This suggests that children in this
age group diagnosed with asthma can be identified reliably
with prescription data. On the contrary, sensitivity and posi-
tive predictive values of the proxies designed for the identifi-
cation of children diagnosed with atopic dermatitis and rhinitis
were lower. The use of prescription data for the identification
of children diagnosed with atopic dermatitis and allergic rhi-
nitis is therefore questionable. This study provides different
medication proxies to aid various epidemiological studies
with the identification of children diagnosed with atopic
diseases.
Interpretation and comparison with literature
Of the different allergic diseases, medication proxies designed
for the identification of asthmatic children yielded highest
accuracy measures, especially for children who were diag-
nosed beyond the age of 5. The evaluation of asthma in young
children is complicated by the lack of objective lung function
measurements [9], explaining the slightly better prediction of
an asthma diagnosis in the older age group. In addition, anti-
asthmatic medicationwas prescribed for other respiratory con-
ditions, like acute bronchitis and cough. Results showed that a
better distinction between different respiratory conditions can
be made with the inclusion of inhaled corticosteroids in the
proxy. In addition, medication proxies can yield higher PPVs
if the proxy includes multiple prescriptions for inhaled asthma
drugs. Accuracy measures of our medication proxies for the
identification of children diagnosed with asthma were compa-
rable with other validation studies [3, 7, 8]. However, our
study showed better accuracy measures in the age group 0–5
than any of the previously performed studies when the proxy
with ≥2 prescriptions for inhaled steroids was applied. Though
asthma cannot be diagnosed objectively before the age of 5, in
the Netherlands, it is a common practice to diagnose children
with recurrent wheeze as being asthmatic. This may explain
the slightly better accuracy measures in the current study. In
addition, the majority of the medication proxies presented in
the current study included the total group of anti-asthma med-
ication rather than specific subtypes of anti-asthma medica-
tion. According to previous studies, the PPV may even be
higher if medication proxies includedmore specific subgroups
of anti-asthma drugs [3]. The medication proxies for the de-
tection of children with atopic dermatitis yielded lower accu-
racy measures. This can mainly be explained by the use of
dermal steroids for other indications than atopic dermatitis,
like the indication contact dermatitis/other dermatitis (ICPC
S88). Since atopic dermatitis is often treated for a longer du-


















































































































































































































































































































































































































































































































Eur J Clin Pharmacol (2016) 72:73–82 77
indications can only be made with a medication proxy that
resembles a long-term treatment (≥4 prescriptions for dermal
steroids). The medication proxy of 4 prescriptions for dermal
corticosteroids within the total time of the study period yielded
an acceptable PPVof 0.75 in the age group 0–10 and an even
higher PPV in the age group 0–5. However, the sensitivity of
Table 4 Number of patients aged 0–10 years that received medication for the treatment of allergic rhinitis, stratified by diagnosis
Diagnosis
Allergic rhinitis Other diseases without concomitant allergic rhinitis
Type of medication Allergic rhinitis ICPC




R07 (N = 263)
Nasal preparations (R01) 752 238 (31.6) 99 (13.2) 85 (11.3)
Nasal anti-allergic preparations (R01AC) 162 103 (63.6) 44 (27.2) 6 (3.7)
Nasal steroids (R01AD) 356 152 (42.7) 43 (12.1) 51 (14.3)
Systemic antihistamines (R06) 1332 301 (22.6) 195 (14.6) 58 (4.4)
Numbers and percentages do not sum up to 100 %, due to multiple medications and diagnoses
ICPC International Classification for Primary Care
Table 5 Accuracymeasures of medication proxies for the identification of children (0–10 years) diagnosed with asthma, atopic dermatitis, and allergic
rhinitis















1 ≥1 inhaled anti-asthma drugs 0.92 (0.90–0.94) 0.54 (0.51–0.57) 0.92 (0.90–0.94) 0.54 (0.51–0.57) 0.92 (0.90–0.94) 0.54 (0.51–0.57)
2 ≥1 inhaled steroid 0.62 (0.59–0.66) 0.76 (0.73–0.80) 0.62 (0.59–0.66) 0.76 (0.73–0.80) 0.62 (0.59–0.66) 0.76 (0.73–0.80)
3 ≥2 inhaled anti-asthma drugs 0.65 (0.62–0.69) 0.75 (0.72–0.79) 0.69 (0.66–0.73) 0.74 (0.70–0.77) 0.75 (0.72–0.78) 0.71 (0.68–0.74)
4 ≥1 inhaled steroid + ≥1 inhaled
other anti-asthma drug
0.52 (0.49–0.55) 0.85 (0.82–0.88) 0.54 (0.50–0.57) 0.84 (0.81–0.87) 0.55 (0.51–0.58) 0.83 (0.80–0.87)
5 ≥3 inhaled anti-asthma drugs 0.45 (0.42–0.49) 0.83 (0.80–0.87) 0.54 (0.50–0.57) 0.82 (0.79–0.85) 0.63 (0.60–0.67) 0.80 (0.77–0.83)
6 ≥2 inhaled steroids 0.43 (0.39–0.46) 0.87 (0.84–0.91) 0.46 (0.43–0.49) 0.87 (0.83–0.90) 0.49 (0.46–0.53) 0.85 (0.82–0.89)
7 ≥4 inhaled anti-asthma drugs 0.33 (0.30–0.36) 0.88 (0.84–0.92) 0.44 (0.40–0.47) 0.86 (0.83–0.90) 0.53 (0.50–0.57) 0.83 (0.80–0.87)
8 ≥5 inhaled anti-asthma drugs 0.23 (0.20–0.26) 0.90 (0.86–0.94) 0.35 (0.32–0.38) 0.90 (0.87–0.93) 0.48 (0.45–0.51) 0.87 (0.83–0.90)
Atopic dermatitis
9 ≥1 dermal steroid 0.80 (0.77–0.82) 0.40 (0.38–0.42) 0.80 (0.77–0.82) 0.40 (0.38–0.42) 0.80 (0.77–0.82) 0.40 (0.38–0.42)
10 ≥1 immunosuppressant 0.01 (0.01–0.02) 0.71 (0.49–0.92) 0.01 (0.01–0.02) 0.71 (0.49–0.92) 0.01 (0.01–0.02) 0.71 (0.49–0.92)
11 ≥2 dermal steroids 0.33 (0.30–0.36) 0.60 (0.56–0.64) 0.40 (0.37–0.43) 0.60 (0.56–0.64) 0.50 (0.47–0.53) 0.57 (0.54–0.60)
12 ≥3 dermal steroids 0.14 (0.12–0.16) 0.71 (0.64–0.77) 0.19 (0.16–0.21) 0.67 (0.61–0.72) 0.31 (0.28–0.34) 0.64 (0.60–0.69)
13 ≥4 dermal steroids 0.06 (0.04–0.07) 0.74 (0.64–0.84) 0.12 (0.10–0.14) 0.75 (0.65–0.85) 0.20 (0.18–0.23) 0.71 (0.65–0.76)
14 ≥5 dermal steroids 0.03 (0.02–0.04) 0.74 (0.61–0.88) 0.06 (0.04–0.07) 0.78 (0.71–0.85) 0.15 (0.13–0.17) 0.77 (0.71–0.83)
Rhinitis
15 ≥1 systemic antihistamine 0.72 (0.68–0.76) 0.23 (0.20–0.25) 0.72 (0.68–0.76) 0.23 (0.20–0.25) 0.72 (0.68–0.76) 0.23 (0.20–0.25)
16 ≥1 nasal antihistamine 0.22 (0.18–0.26) 0.87 (0.81–0.93) 0.22 (0.18–0.26) 0.87 (0.81–0.93) 0.22 (0.18–0.26) 0.87 (0.81–0.93)
17 ≥1 nasal steroid 0.36 (0.32–0.41) 0.43 (0.38–0.48) 0.36 (0.32–0.41) 0.43 (0.38–0.48) 0.36 (0.32–0.41) 0.43 (0.38–0.48)
18 ≥2 systemic antihistamines, nasal
antihistamines or nasal steroids
0.53 (0.49–0.58) 0.47 (0.42–0.51) 0.59 (0.54–0.64) 0.43 (0.39–0.47) 0.67 (0.62–0.71) 0.40 (0.36–0.43)
19 ≥3 systemic antihistamines, nasal
antihistamines or nasal steroids
0.34 (0.29–0.38) 0.61 (0.54–0.67) 0.40 (0.35–0.45) 0.57 (0.51–0.62) 0.52 (0.47–0.57) 0.50 (0.46–0.55)
20 ≥2 nasal steroids 0.16 (0.12–0.19) 0.59 (0.50–0.68) 0.18 (0.14–0.22) 0.60 (0.51–0.68) 0.20 (0.16–0.24) 0.57 (0.49–0.65)
21 ≥4 systemic antihistamines, nasal
antihistamines or nasal steroids
0.19 (0.15–0.23) 0.67 (0.58–0.75) 0.27 (0.23–0.31) 0.63 (0.56–0.70) 0.40 (0.36–0.45) 0.58 (0.52–0.64)
22 ≥5 systemic antihistamines, nasal
antihistamines or nasal steroids
0.13 (0.10–0.16) 0.71 (0.60–0.81) 0.18 (0.15–0.22) 0.65 (0.56–0.73) 0.34 (0.30–0.39) 0.62 (0.56–0.69)
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this proxy was really low (0.12). Hence, consideration should
be made if its use is feasible, since only a really small percent-
age of children with a diagnosis of atopic dermatitis will be
detected. This medication proxy may only be applied in large
databases. Only one previous study validated a medication
proxy for the identification of children diagnosed with atopic
dermatitis and reported a PPV of 0.45 [8]. The PPV of the




















Number of prescripons of an-asthma medicaon
Sensivity
PPV
Fig. 1 Development of
sensitivity and positive predictive
value (PPV) with an increasing
number of anti-asthma
prescriptions within 1 year
Table 6 Accuracy measures of medication proxies for the identification of children diagnosed with asthma, atopic dermatitis, and allergic rhinitis for
children aged 0–5 and children aged 5–10
1-year capture period










1 ≥1 inhaled anti-asthma drugs 0.90 (0.87–0.92) 0.48 (0.45–0.51) 0.94 (0.91–0.96) 0.71 (0.67–0.75)
2 ≥1 inhaled steroid 0.58 (0.54–0.62) 0.71 (0.67–0.75) 0.68 (0.63–0.72) 0.84 (0.80–0.88)
3 ≥2 inhaled anti-asthma drugs 0.64 (0.60–0.68) 0.67 (0.63–0.71) 0.75 (0.71–0.79) 0.85 (0.81–0.89)
4 ≥1 inhaled steroid + ≥1 inhaled other anti-asthma drug 0.49 (0.45–0.53) 0.79 (0.75–0.84) 0.57 (0.52–0.61) 0.89 (0.85–0.93)
5 ≥3 inhaled anti-asthma drugs 0.49 (0.45–0.53) 0.77(0.73–0.81) 0.58 (0.53–0.63) 0.88 (0.84–0.92)
6 ≥2 inhaled steroids 0.43 (0.39–0.47) 0.81 (0.77–0.86) 0.51 (0.46–0.56) 0.92 (0.89–0.96)
7 ≥4 inhaled anti-asthma drugs 0.39 (0.35–0.43) 0.82 (0.77–0.87) 0.50 (0.45–0.54) 0.91 (0.87–0.95)
8 ≥5 inhaled anti-asthma drugs 0.30 (0.26–0.34) 0.85 (0.81–0.90) 0.40 (0.35–0.45) 0.94 (0.90–0.97)
Atopic dermatitis
9 ≥1 dermal steroid 0.78 (0.75–0.81) 0.45 (0.43–0.48) 0.77 (0.72–0.82) 0.29 (0.26–0.33)
10 ≥1 immunosuppressant 0.01 (0.00–0.02) 0.78 (0.51–1.05) 0.02 (0.00–0.03) 0.63 (0.29–0.96)
11 ≥2 dermal steroids 0.40 (0.36–0.43) 0.65 (0.61–0.70) 0.37 (0.31–0.42) 0.48 (0.41–0.54)
12 ≥3 dermal steroids 0.19 (0.16–0.22) 0.72 (0.66–0.78) 0.15 (0.11–0.19) 0.52 (0.41–0.62)
13 ≥4 dermal steroids 0.12 (0.10–0.14) 0.71 (0.60–0.82) 0.09 (0.06–0.12) 0.71 (0.57–0.85)
14 ≥5 dermal steroids 0.06 (0.04–0.07) 0.71 (0.60–0.82) 0.04 (0.02–0.06) 0.72 (0.52–0.93)
Rhinitis
15 ≥1 systemic antihistamine 0.71 (0.63–0.78) 0.12 (0.09–0.14) 0.70 (0.65–0.75) 0.33 (0.30–0.37)
16 ≥1 nasal antihistamine 0.11 (0.05–0.16) 0.78 (0.59–0.97) 0.25 (0.21–0.30) 0.90 (0.83–0.96)
17 ≥1 nasal steroid 0.20 (0.13–0.26) 0.28 (0.19–0.37) 0.38 (0.33–0.44) 0.45 (0.39–0.51)
18 ≥2 systemic antihistamines, nasal antihistamines or nasal steroids 0.47 (0.38–0.55) 0.23 (0.18–0.28) 0.61 (0.56–0.67) 0.55 (0.50–0.60)
19 ≥3 systemic antihistamines, nasal antihistamines or nasal steroids 0.30 (0.22–0.38) 0.35 (0.26–0.44) 0.42 (0.37–0.47) 0.64 (0.58–0.71)
20 ≥2 nasal steroids 0.11 (0.05–0.16) 0.61 (0.41–0.81) 0.19 (0.15–0.23) 0.57 (0.47–0.66)
21 ≥4 systemic antihistamines, nasal antihistamines or nasal steroids 0.16 (0.10–0.22) 0.36 (0.24–0.49) 0.33 (0.25–0.35) 0.68 (0.61–0.76)
22 ≥5 systemic antihistamines, nasal antihistamines or nasal steroids 0.11 (0.06–0.17) 0.42 (0.26–0.58) 0.21 (0.17–0.25) 0.70 (0.61–0.79)
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explained by the fact that the medication proxy designed in the
current study resembled long-term treatment.
This is the first study that validated medication proxies
designed for the identification of children diagnosed with al-
lergic rhinitis. The medication proxy ≥1 prescription for nasal
antihistamines yielded a high PPV of 0.87 (95 % CI 0.81–
0.93). However, similar to the medication proxy for atopic
dermatitis, the sensitivity is low (0.22) and its use is
questionable.
Strengths and limitations
The major strength of the current study is the validity testing
of a wide range of medication proxies for the identification of
children diagnosed with different atopic diseases. Previous
studies that validated medication proxies for the identification
of children with asthmamainly validated proxies applicable in
etiological research and focused on PPVs. Though many stud-
ies focus on etiological research, proxies which prioritize sen-
sitivity over PPV may also be useful. To our knowledge, this
is the first study that validated medication proxies for the
identification of children diagnosed with allergic rhinitis and
the second to validate the identification of children diagnosed
with atopic dermatitis with prescribing data.
The RNG database is representative for the Netherlands as
a whole, and results are generalizable to the Dutch childhood
population. Since prescribing guidelines differ between coun-
tries, it should be noted that findings from our study may be at
least in part specific for the situation in the Netherlands.
Though misclassification can occur in every database, the
coding of ICPC and ATC codes by the GPs in the RNG data-
base was proven to be accurate by previous studies [7, 13].
Though GPs in the RNG database have been trained specifi-
cally to work with the coding system, behavior of diagnosing
and prescribing may vary between practices and influence
accuracy measures of the medication proxies. Nonetheless,
additional analyses detected no difference between the prac-
tices (percentages of truly positive identified asthma patients
varied from 8.6 until 11.1 % between practices) in identifying
diagnosed asthmatic children with the medication proxy ≥1
prescription for anti-asthma drugs (data on file).
Implications for future research
The selection of a particular medication proxy will always
depend on the focus of interest of a study and the available
data sources. Though studies that require maximizing one
accuracy measure completely at the expense of another are
rare, there are situations in which one accuracy measure may
be more important than the other [10]. In the following sce-
narios, we discuss the applicability of the presented proxies
for future research.
The sensitivity of a proxy may be given more importance if
the goal is to identify all patients with a certain condition in a
population. The proxy ≥1 prescription for anti-asthmatic drugs
detects 92 % of the children with an asthma diagnosis. As a
consequence, 46 % of the included cases are false positives.
This may not be a problem if additional verification, like a
personal interview, takes place after inclusion. Another sce-
nario that requires a proxy with a high sensitivity is if the aim
is to assess the full range of disease outcomes rather than only
the most severe. Less sensitive proxies may detect only the
severe outcomes, so results may not be generalizable to the
whole patient population. This may be important when, for
example, a study focusses on the effectiveness of asthma treat-
ment. A proxy with a low sensitivity may fail to detect the
effectiveness of asthma treatment that works for mild but not
for severe asthma cases. For atopic dermatitis and allergic
rhinitis, medication proxies that yielded acceptable sensitivity
values yielded low PPVs. The applicability of these proxies
for future research is questionable, since more than half of the
included patients will be false positives. Therefore, additional
verification of the condition should take place after inclusion.
The PPVof a proxy may be given more importance over
the sensitivity of a proxy when a study aims to identify
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Fig. 2 Sensitivity of the PPV for
childhood asthma as a function of
the prevalence for a range of
values [20]. Positive predictive
values were derived from the
proxy ≥2 inhaled steroids in a
year
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representative of all persons that have the condition. In
etiological studies, researchers want to ensure that the chil-
dren that are defined as cases do actually have the disease
[21]. A proxy with a low PPV includes more false positives
and may fail to detect an association between the exposure
and the outcome, since this would bias the effect estimate
towards the null. For asthma, the proxy ≥2 inhaled steroids
within a year can be applied since it yielded a high PPV
(0.87) and still half of the patients diagnosed with asthma
were detected. However, the proxies that yielded satisfac-
tory PPVs for atopic dermatitis and allergic rhinitis yielded
low sensitivity values. Hence, it should be considered if its
use is feasible, since only a really small percentage of chil-
dren with a diagnosis of these conditions will be detected.
Since the PPV is an indirect accuracy measure and depen-
dent on the sensitivity and specificity, it cannot be influ-
enced directly by the researcher. In addition, the PPV is
influenced by the prevalence of the condition, which may
vary between different populations. However, sensitivity
analyses of varying prevalence of the disease on the PPV
of the proxy showed that PPVs were satisfactory over a
reasonable range of prevalence numbers of asthma (Fig. 2).
Since the specificity and NPVs were artificially high due to
the large number of non-allergic patients included in the study
population, we did not calculate these accuracy measures and
no recommendations can be made for these accuracy
measures.
In conclusion, this study showed that children diagnosed
with asthma can be identified reliably with a range of medi-
cation proxies. The use of prescription data for the identifica-
tion of children diagnosed with atopic dermatitis and allergic
rhinitis is questionable, since sufficient PPVs were only
yielded in combination with low sensitivity values. Data col-
lection for childhood patients is challenging, and prescription
databases may provide convenient and easily available
sources. The broad spectrum of medication proxies presented
in this study may aid various epidemiological studies with the
identification of children diagnosed with allergic disorders in
the future.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg
LT, Postma MJ (2013) The population-based prescription database
IADB.nl: its development, usefulness in outcomes research and
challenges. Expert Rev Pharmacoecon Outcomes Res 13(3):285–
292
2. Zuidgeest MG, van Dijk L, Smit HA, et al. (2008)
Prescription of respiratory medication without an asthma di-
agnosis in children: a population based study. BMC Health Serv
Res 8:16
3. Bianchi M, Clavenna A, Sequi M, Bonati M (2011) Asthma diag-
nosis vs. analysis of anti-asthmatic prescriptions to identify asthma
in children. Eur J Clin Pharmacol 67:967–968
4. Osborne ML, Vollmer WM, Johnson RE, Buist AS (1995) Use of
an automated prescription database to identify individuals with
asthma. J Clin Epidemiol 48:1393–1397
5. Pont LG, van der Werf GT, Denig P, Haaijer-Ruskamp FM (2002)
Identifying general practice patients diagnosed with asthma and
their exacerbation episodes from prescribing data. Eur J Clin
Pharmacol 57(11):819–825
6. Furu K, Skurtveit S, Langhammer A, Nafstad P (2007) Use
of anti-asthmatic medications as a proxy for prevalence of
asthma in children and adolescents in Norway: a nationwide
prescription database analysis. Eur J Clin Pharmacol 63(7):
693–698
7. Moth G, Vedsted P, Schiøtz P (2007) Identification of asthmatic
children using prescription data and diagnosis. Eur J Clin
Pharmacol 63(6):605–611
8. Örtqvist AK, Lundholm C, Wettermark B, Ludvigsson JF, Ye W,
Almqvist C (2013) Validation of asthma and eczema in population-
based Swedish drug and patient registers. Pharmacoepidemiol Drug
Saf 22(8):850–860
9. Bacharier LB, Guilbert TW (2012) Diagnosis and management of
early asthma in preschool-aged children. J Allergy Clin Immunol
130(2):287–296
10. Chubak J, Pocobelli G, Weiss NS (2012) Tradeoffs between accu-
racy measures for electronic health care data algorithm. J Clin
Epidemiol 65(3):343–349
11. Bantz SK, Zhu Z, Zheng T (2014) The atopic March: progression
from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell
Immunol 5(2)
12. World Organisation of Family Doctors (WONCA) (1998) ICPC-2:
International Classification of Primary Care, 2nd edn. Oxford
University Press, Oxford
13. Schokker S, Groenhof F, van der VeenWJ, van der Molen T (2010)
Prescribing of asthma medication in primary care for children aged
under 10. Prim Care Respir J 19(1):28–34
14. Schrijvers AJP (ed) (1997) Health and health care in the
Netherlands: a critical self-assessment of Dutch experts in
medical and health sciences. De Tijdstroom, Utrecht,
The Netherlands
15. Van-der-Werf GT, Smith RJA, Stewart RE, Meyboom-de Jong B
(1998) Spiegel op de huisarts: over registratie van ziekte, medicatie
en verwijzingen in de geautomatiseerde huisartspraktijk.
Groningen, The Netherlands
16. Pont LG, Denig P, van der Molen T, van der Veen WJ, Haaijer-
Ruskamp FM (2004) Validity of performance indicators for
assessing prescribing quality: the case of asthma. Eur J Clin
Pharmacol 59(11):833–840 Epub 2003 Nov 18
17. NHG (Dutch General Practitioner Guidelines). https://www.nhg.
org/standaarden/volledig/nhg-standaard-astma-bij-kinderen. Last
accessed 24th April 2015.
18. NHG (Dutch General Practitioner Guidelines). https://www.nhg.
org/standaarden/volledig/nhg-standaard-constitutioneel-eczeem.
Last accessed 24th April 2015.
19. NHG (Dutch General Practitioner Guidelines). https://www.nhg.
org/standaarden/volledig/nhg-standaard-allergische-en-niet-
allergische-rhinitis. Last accessed 24th April 2015.
20. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP,
Weiland SK, Williams H (2006) ISAAC phase three study
Eur J Clin Pharmacol (2016) 72:73–82 81
group. Worldwide time trends in the prevalence of symptoms
of asthma, allergic rhinoconjunctivitis, and eczema in child-
hood: ISAAC phases one and three repeat multicountry
cross-sectional surveys. Lancet 368(9537):733–743
21. Mulder B, Schuiling-Veninga CC, Bos HJ, De Vries TW, Jick SS,
Hak E (2014) Prenatal exposure to acid-suppressive drugs and the
risk of allergic diseases in the offspring: a cohort study. Clin Exp
Allergy 44(2):261–269
82 Eur J Clin Pharmacol (2016) 72:73–82
